Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
79.80    2.10 (2.70%)
Bid:
79.90
Ask:
81.20
Spread: 1.30 (1.627%)
Market Cap: £130.83m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Disposal

11 Feb 2008 07:01

Yule Catto & Co PLC11 February 2008 Yule Catto & Co. plc Sale of James Robinson Yule Catto is an international producer of speciality chemicals, supplied toglobal customers for use in a wide range of industries includingpharmaceuticals, FMCG, paints and adhesives Yule Catto & Co plc ("Yule Catto" or the "Company") is pleased to announce thatit has exchanged conditional contracts with Vivimed Labs Limited ("Vivimed") forthe sale of the entire issued share capital of James Robinson Limited and otherassociated assets (together "James Robinson") for a consideration of $21.15million plus working capital of approximately $4.5 million. The considerationwill be paid as to $17.15 million plus the working capital amount in cash atcompletion and a further $4 million into escrow pending successful completion ofcertain product transfer arrangements. The completion of the sale is conditional on, amongst other things, Vivimedobtaining shareholder approval for the acquisition which is expected to beobtained by mid April 2008. The proceeds of the sale received by Yule Catto will be used to reduce theCompany's borrowings, and the transaction will be earnings accretive James Robinson carries on the development, manufacture and supply ofphotographic and photochromic chemicals and hair and other dyes. In the twelvemonths to 31 December 2006 it had sales of £17.8 million, an operating profit of£0.82 million and gross assets of £3.0 million. The James Robinson management team led by Dr Richard Smith will continue to runthe business. In addition, Yule Catto anticipates disposing of its interest in James RobinsonIndia (Private) Limited to its joint venture partner following the completion ofthe sale of James Robinson for a consideration of some $1.5 million. Adrian Whitfield, Chief Executive commented: "This sale is in line with YuleCatto's corporate strategy of delivering improved shareholder value from itsImpact Chemicals activities". 11 February 2008 ENQUIRIES: YULE CATTO Tel: 01279 442791Adrian Whitfield, Chief ExecutiveDavid Blackwood, Finance Director COLLEGE HILL Tel: 020 7457 2020Gareth DavidAnthony Parker This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
10th Oct 202310:26 amRNSHolding(s) in Company
9th Oct 20233:08 pmRNSHolding(s) in Company
9th Oct 20239:44 amRNSHolding(s) in Company
6th Oct 20231:56 pmRNSHolding(s) in Company
6th Oct 20238:53 amRNSHolding(s) in Company
5th Oct 20232:40 pmRNSDirector/PDMR Shareholding
5th Oct 202312:27 pmRNSHolding(s) in Company
2nd Oct 20232:22 pmRNSHolding(s) in Company
28th Sep 20237:00 amRNSAdmission of Nil Paid Rights
27th Sep 20237:00 amRNSDespatch of PALs
26th Sep 20237:00 amRNSCapital Reorganisation
25th Sep 20231:58 pmRNSResults of General Meeting
22nd Sep 20233:21 pmRNSAdditional Listing
7th Sep 20233:44 pmRNSPublication of a Prospectus
7th Sep 20237:00 amRNSRights Issue
7th Sep 20237:00 amRNSHalf-year results
18th Jul 20237:00 amRNSPost-close trading update
12th Jul 20233:17 pmRNSAppointment of Non-Executive Director
28th Jun 202312:37 pmRNSDirector/PDMR Shareholding
28th Jun 202312:36 pmRNSDirector/PDMR Shareholding
22nd Jun 202310:20 amRNSDirector/PDMR Shareholding
16th May 20234:00 pmRNSResult of AGM
16th May 20237:00 amRNSAGM trading update
12th May 20231:08 pmRNSDirector/PDMR Shareholding
12th May 20231:06 pmRNSDirector/PDMR Shareholding
13th Apr 202310:02 amRNSHolding(s) in Company
12th Apr 20235:52 pmRNS2022 Annual Financial Report & Notice of 2023 AGM
11th Apr 20237:00 amRNSDirector/PDMR Shareholding
11th Apr 20237:00 amRNSDirector/PDMR Shareholding
29th Mar 20237:00 amRNSDirector/PDMR Shareholding
29th Mar 20237:00 amRNSDirector/PDMR Shareholding
29th Mar 20237:00 amRNSDirector/PDMR Shareholding
28th Mar 20237:00 amRNSFinal Results
21st Mar 20237:00 amRNSRefinancing
28th Feb 20233:33 pmRNSDisposal
31st Jan 20237:00 amRNSPost-close update for the year ended 31 Dec 2022
11th Jan 202311:30 amRNSResult of General Meeting
16th Dec 202212:12 pmRNSPublication of Circular &Notice of General Meeting
13th Dec 20227:00 amRNSProposed Sale of Laminates, Films & Coated Fabrics
8th Dec 20227:00 amRNSDirector/PDMR Shareholding
30th Nov 20227:00 amRNSBoard changes
29th Nov 202211:16 amRNSOutcome of European Commission investigation
1st Nov 20222:53 pmRNSHolding(s) in Company
27th Oct 202210:27 amRNSHolding(s) in Company
25th Oct 20227:00 amRNSDirector/PDMR Shareholding
25th Oct 20227:00 amRNSDirector/PDMR Shareholding
20th Oct 20227:00 amRNSCovenant relaxation to the end of 2023 agreed
13th Oct 20227:00 amRNSHolding(s) in Company
12th Oct 20227:00 amRNSInvestor Seminar
6th Oct 20227:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.